Comparison of Autologous Serum Eye Drops with Different Diluents

Cho, Yang Kyung; Huang, Wei; Kim, Geun Yeong; Lim, Byung Su

doi:10.3109/02713683.2012.720340

Cited by 69 publications

(67 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, administration of artificial tears, viscoelastic (such as hyaluronan or chondroitin sulfate) eyedrops, punctal plugs (Tai et al, 2002), and fibrin glue (Sumich et al, 2003) as well as improved lid hygiene have been tried. Autologous serum eyedrops (Geerling et al, 2004;Matsumoto et al, 2004;Mukerji et al, 2002;Noble et al, 2004), umbilical cord serum (Vajpayee et al, 2003;Yoon et al, 2005Yoon et al, , 2007, EGF (Daniele et al, 1992), and plasma rich in growth factors (Cho et al, 2013;Geerling et al, 2004;Kim et al, 2012;Lopez-Plandolit et al, 2010;Mukerji et al, 2002;Poon et al, 2001;Tsubota et al, 1999b;Vajpayee et al, 2003) have also been examined in the clinical setting, but none of these treatment modalities has been confirmed to be effective scientifically (Pan et al, 2013).…”

Section: Persistent Corneal Epithelial Defects (Nonhealing Epithelialmentioning

confidence: 98%

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Nishida

Inui

Nomizu

2015

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

The condition of the corneal epithelium is a critical determinant of corneal transparency and clear vision. The corneal epithelium serves as a barrier to protect the eye from external insults, with its smooth surface being essential for its optical properties. Disorders of the corneal epithelium include superficial punctate keratopathy, corneal erosion, and persistent epithelial defects (PEDs). The prompt resolution of these disorders is important for minimization of further damage to the cornea. Currently available treatment modalities for corneal epithelial disorders are based on protection of the ocular surface in order to allow natural healing to proceed. PEDs remain among the most difficult corneal conditions to treat, however. On the basis of characterization of the pathobiology of PEDs at the cell and molecular biological levels, we have strived to develop new modes of treatment for these defects. These treatments rely on two key concepts: provision of a substrate, such as the adhesive glycoprotein fibronectin, for the attachment and migration of corneal epithelial cells, and activation of these cells by biological agents such as the combination of substance P and insulin-like growth factor-1 (IGF-1). Central to both approaches is the role of the fibronectin-integrin system in corneal epithelial wound healing. Determination of the minimum amino acid sequences required for the promotion of corneal epithelial wound closure by fibronectin (PHSRN) and by substance P (FGLM-amide) plus IGF-1 (SSSR) has led to the development of peptide eyedrops for the treatment of PEDs that are free of adverse effects of the parent molecules.

show abstract

Section: Persistent Corneal Epithelial Defects (Nonhealing Epithelialmentioning

confidence: 98%

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Nishida

Inui

Nomizu

2015

Progress in Retinal and Eye Research

View full text Add to dashboard Cite

show abstract

“…Numerous studies 19,20,[22][23][24][25][26][27][28]45 involving humans with persistent corneal epithelial defects have revealed beneficial effects of topically applied serum on epithelial healing, but epithelial deficiency may not be a primary contributor to the pathogenesis of SCCED in dogs. Although abnormal histologic features have been demonstrated in the epithelium of up to 94% of dogs with SCCED, 6 similar findings have also been reported for dogs with chronic, experimentally induced corneal wounds.…”

Section: Discussionmentioning

confidence: 99%

Effects of topically applied heterologous serum on reepithelialization rate of superficial chronic corneal epithelial defects in dogs

Eaton

Hollingsworth

Holmberg³

et al. 2017

javma

View full text Add to dashboard Cite

OBJECTIVE To assess the effects of topical application of undiluted heterologous serum on time to corneal reepithelialization in dogs with superficial chronic corneal epithelial defects (SCCEDs). DESIGN Multicenter, randomized, double-masked, controlled clinical trial. ANIMALS 41 client-owned dogs. PROCEDURES After collection of baseline clinical and historical data, dogs were randomly assigned to receive topically applied undiluted heterologous serum (n = 22) or isotonic saline (0.9% NaCl) solution (19) along with tobramycin and atropine. Epithelial debridement (at all visits) and grid keratotomy (at visits 2, 3, and 4) of SCCEDs were performed. Ophthalmic examination including fluorescein application was performed once weekly for 4 weeks or until corneal reepithelialization. Clinicians and owners were masked to treatment group. RESULTS No differences in baseline data were detected between treatment groups. No difficulties with medication administration, noncompliance, or adverse reactions were noted. All SCCEDs in both groups healed by 4 weeks after treatment began. Median time to reepithelialization (2 weeks) was not significantly different between serum-treated and placebo-treated eyes. Irrespective of treatment group, median time to reepithelialization was not significantly different for Boxers versus non-Boxer breeds. Direct correlations were detected between time to reepithelialization and vascularization score at study entry, vascularization score at time of reepithelialization, and ulcer area at study entry in both groups. Time to reepithelialization was not correlated with age, sex, or duration of signs in either group. CONCLUSIONS AND CLINICAL RELEVANCE Topical application of undiluted heterologous serum was well tolerated by dogs with SCCEDs but, as an adjunct to standard treatment, did not reduce time to corneal reepithelialization.

show abstract

“…In a recent study comparing different concentrations, 50 % AS with sodium hyaluronate was more effective than artificial tears in reducing symptoms, corneal epitheliopathy and promoting fast closure of corneal wounds in non-Sjögren patients, while in Sjögren patients 100 % serum was the more effective choice. 46,47 Exactly the optimal concentration of AS eye drops is not clearly known in the treatment of severe DED. An important component of AS eye drops which makes the dilution of AS to 20 % necessary is transforming growth factor beta (TGF-β).…”

Section: Management Of Dry Eye Diseasementioning

confidence: 99%

“…That is one of the reasons why 20 % dilution was used in a whole of the previous AS studies in the literature. 46,47 Punctal plugs may be used with caution in severe DED. Silicone or collagen plugs could be used initially for a trial period, and then a permanent punctal occlusion with cautery should be considered.…”

Section: Management Of Dry Eye Diseasementioning

confidence: 99%

Dry Eye and Clinical Disease of Tear Film, Diagnosis and Management

Achtsidis¹,

Kozanidou²,

Bournas³

et al. 2014

European Ophthalmic Review

View full text Add to dashboard Cite

Dry eye disease (DED) is a clinically significant multifactorial disorder of the ocular surface and tear film as it results in ocular discomfort and visual impairment and predisposes the cornea to infections. It is important for the quality of life and tends to be a chronic disease. It is also common, as the prevalence is estimated between 5 % to 30 % and this increases with age. Therefore, it is recognised as a growing public health problem that requires correct diagnosis and appropriate treatment. There are two main categories of DED: the deficiency of tear production (hyposecretive), which includes Sjögren syndrome, idiopathic or secondary to connective tissue diseases (e.g. rheumatoid arthritis), and non-Sjögren syndrome (e.g. age-related); and the tear evaporation category, where tears evaporate from the ocular surface too rapidly due to intrinsic causes (e.g. meibomian gland disease or eyelid aperture disorders) or extrinsic causes (e.g. vitamin A deficiency, contact lenses wear, ocular allergies). Management of the disease aims to enhance the corneal healing and reduce patient's discomfort. This is based on improving the balance of tear production and evaporation by increasing the tear film volume (lubrication drops) and improving quality of tear film (ex omega-3 supplements, lid hygiene, tetracyclines), reducing the tear film evaporation (paraffin ointments, therapeutic contact lenses), reducing tear's drainage (punctal plugs, cautery) and finally by settling down the ocular surface inflammation (steroids, cyclosporine, autologous serous), as appropriate. In this article we will review the clinical presentation, differential diagnosis and treatment options for DED. KeywordsDry eye disease, tear film, Sjögren, ocular inflammation. There is now an increased recognition by clinicians that dry eye disease (DED) is a common disorder characterised by dryness and damage of the ocular surface. It affects quality of life, including aspects of physical, social and psychological functioning, because it induces ocular discomfort, burning sensation, light sensitivity, visual disturbances or even corneal erosions and infections. DED is also known as keratoconjunctivitis sicca, dry eye syndrome and dysfunctional tear syndrome. DED prevalence has been reported to range from 5 % to 30 %, this being a likely result from differing study populations and DED definitions. In a large population study, Moss et al. reported the prevalence of dry eye to be 14.4 % in 3,722 subjects aged 48 to 91 years and noted that the prevalence of the condition doubled after the age of 59. As a consequence, DED prevalence is expected to increase in ageing populations, which will eventually make this health problem more prominent. [1][2][3][4] In order to address the problem, the International Dry Eye Workshop (DEWS) defines dry eye as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance and tear film instability with potential damage to the ocular surface. It is accompanied ...

show abstract

Comparison of Autologous Serum Eye Drops with Different Diluents

Cited by 69 publications

References 29 publications

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Peptide therapies for ocular surface disturbances based on fibronectin–integrin interactions

Effects of topically applied heterologous serum on reepithelialization rate of superficial chronic corneal epithelial defects in dogs

Dry Eye and Clinical Disease of Tear Film, Diagnosis and Management

Contact Info

Product

Resources

About